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Abstract Diabetes is a common and rapidly growing disease
that affects more than 380 million people worldwide and is an
established risk factor for cardiovascular disease with differ-
ential effects on women compared to men. While the general
population of women, particularly young women, has more
favourable cardiovascular risk profiles than men, this protec-
tive effect has been shown to be lost or even reversed in
diabetic women. Several studies have demonstrated a signifi-
cant diabetes-associated excess risk of cardiovascular disease
in women. Sex-specific differences in risk factors associated
with diabetes and their management may be responsible for
the relative excess cardiovascular risk in women with diabe-
tes. Diabetic women need intensive treatment in order to op-
timize management of cardiovascular risk factors. Further
studies are needed to elucidate the mechanisms underlying
the excess cardiovascular risk in diabetic women in order to
tailor prevention and treatment strategies.
Keywords Diabetes . Cardiovascular risk .Women . Sex
differences
Introduction
Diabetes is a common and rapidly growing disease [1]. The
International Diabetes Federation has projected that the
number of people with diabetes in the world will increase
from 387 million in 2014 to 592 million by 2035 [2]. The
World Health Organization (WHO) reported a global prev-
alence of 9 % in 2014 [3]. There are two main forms of
diabetes. Type 1 diabetes is due primarily to auto-immune-
mediated destruction of pancreatic beta-cells resulting in
insulin deficiency. Type 2 diabetes is characterized by in-
sulin resistance and abnormal insulin secretion and ac-
counts for 85–95 % of diabetes cases globally [4•]. Both
types of diabetes are on the increase, type 2 diabetes in
particular.
Apart from the heightened genetic susceptibility of certain
ethnic groups, environmental and behavioural factors such as
sedentary lifestyle and nutrition are responsible for the diabe-
tes epidemic.
Individuals with diabetes have an increased risk of de-
veloping a number of disabling and life-threatening health
problems, including serious diseases affecting the cardio-
vascular system, eyes, kidneys, and nerves. Evidence for
an excess risk of cardiovascular disease associated with
diabetes in women is increasing, an observation that urges
intensified treatment and management of female diabetes
patients. This review summarizes the evidence of sex dif-
ferences in diabetes-associated risk of cardiovascular dis-
ease and provides possible explanations for the excess risk
in women that may provide female-specific targets for
prevention and treatment. It also highlights the importance
of sex-specific analysis in trials and observational studies
of treatment and control of cardiovascular risk factors in
persons with diabetes and gives recommendations for
future research.
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Epidemiology of Diabetes
Type 1 diabetes occurs predominantly in children and young
adults. Incidence rates vary widely and range from 0.1/100,
000 per year in Chinese regions to more than 40/100,000 per
year in Finland [5]. Age-specific incidence rates do not differ
between the sexes up to 14 years of age in most studies [6].
However, at older ages, male excess is a constant finding in
populations of European origin [7–10].
Type 2 diabetes is a multifactorial and heterogeneous dis-
ease. It is often a manifestation of clustering of disorders,
including hyperinsulinaemia, dyslipidaemia, hypertension,
visceral obesity, hypercoagulability and microalbuminuria.
The diabetes epidemic and the potential for increases in num-
bers of cases, although apparent around the world, are most
pronounced in non-Caucasian populations [11]. The global
prevalence of diabetes was 8 % in 2013 and reached 35 %
in some regions [4]. Overall, there is little sex difference in the
global numbers of people with type 2 diabetes. The prevalence
rises with age and is slightly higher in men up to the age of 70
[4]. The global prevalence in men 50 years of age was about
15 % compared to 13 % in their female counterparts. Due to
the long time period that frequently elapses before diabetes is
detected, a substantial number of cases may be undiagnosed.
Diabetes is a major global cause of premature death that is
easily underestimated because only a minority of patients with
diabetes die from a cause uniquely related to the condition.
Diabetes is a stronger risk factor for all-cause mortality in
women than in men [12]. According to global WHO esti-
mates, in 2012, diabetes caused 684,346 deaths in men and
813,025 deaths in women, representing 2.3 and 3.1 % of all
deaths in men and women, respectively [3]. However, the
number of deaths caused by diabetes could be underestimated
because attributing deaths to diabetes is challenging. Using a
modelling approach, the International Diabetes Federation es-
timated that the number of deaths caused by diabetes in 2013
was 5.1 million among people aged 20–79 years, accounting
for 8.4 % of global all-cause mortality among people in this
age group [4, 13]. Diabetes accounts for a larger proportion of
deaths in women than in men over 49 years of age, affecting
over 25 % of women in some regions and age groups [13].
Excess Cardiovascular Risk in Women with Diabetes
The leading cause of morbidity and mortality among people
with diabetes is cardiovascular disease [14, 15]. Approximate-
ly one half of individuals with type 2 diabetes will die of a
cardiovascular cause [16]. It has been reported that diabetes
confers an equivalent risk to ageing 15 years [17]. In the
general population, cardiovascular disease events occur years
later in women than in men. In 2012, a large study evaluating
the impact of sex on cardiovascular outcomes in high-risk
patients under optimal standard treatment (n=31,546; 30 %
women; >55 years) demonstrated better outcomes in women
than in men [18••]. Kappert et al. combined two parallel trials
(ONTARGET and TRANSCEND) cohorts of individuals at
high risk of a major cardiovascular event on the basis of one or
more of the following: history of coronary artery disease, pe-
ripheral vascular disease, stroke or transient ischemic attack,
or diabetes mellitus with end-organ complications. The com-
bined risk of cardiovascular death, myocardial infarction (MI)
and stroke was significantly lower (−21 %) in women than in
men. Similarly, the risk for MI was 22 % lower in female than
in male patients. Furthermore, women experienced the end
points on average 5 to 10 years later [18••]. This finding is
in line with data obtained from the INTERHEART study (n=
27,098; 25 % women), a case-control study that showed a
delay of 9 years in occurrence of the first acute MI in women
compared to men [19].
Studies have consistently found that individuals with dia-
betes have a higher risk of morbidity and mortality due to
cardiovascular disease compared with those without diabetes
[14, 15]. Moreover, several studies have demonstrated that
diabetes greatly attenuates, or may even reverse, the protective
effect of female sex on cardiovascular risk [17, 18••, 19]. The
study of Kappert et al. [18••], in agreement with the INTE
RHEART study [19], showed that diabetes altered the sex
differences in cardiovascular outcomes: while the risk of MI
was substantially lower in female vs. male non-diabetic per-
sons, diabetic women were at significantly greater risk of de-
veloping MI compared to diabetic men. In a recent meta-anal-
ysis, the excess risk of fatal cardiovascular disease in persons
with type 1 diabetes was twice as high in women compared
withmen [20••]. In the past 15 years, three meta-analyses have
examined the relative risk of fatal coronary heart disease as-
sociated with diabetes in women vs. men. All these studies
point toward an increased risk in women, but only two of the
three reported a significant difference (up to 50 %) after ad-
justment for classic cardiovascular risk factors [21–23]. In
2014, a meta-analysis (data from 64 studies, n=858,507 indi-
viduals, n=28,203 events) showed that the relative risk of
incident coronary heart disease was 44 % greater in diabetic
women than in diabetic men [24••]. Another meta-analysis
(data from 7 studies, n=59,383 individuals, n=1427 events)
found an even greater (2.5-fold) excess risk of incident coro-
nary heart disease in women compared to men with type 1
diabetes [20••].
Stroke is another well-known diabetes-associated outcome
[25]. In contrast to MI, contradictory findings have been re-
ported on sex differences in diabetes-related risk for stroke,
claiming decreased [26, 27], equal [28] or increased [29, 30]
risk in diabetic women compared with men. However, the
most recent systematic reviews reported that the excess risk
of stroke is 27 % greater in women with diabetes of all types
(data from 64 studies, n=775,385 individuals, n=12,539
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events) [31] and 37 % greater in women with type 1 diabetes
(data from 4 studies, n=45,677 individuals, n=371 events)
[20••] compared with their male counterparts, independent
of sex differences in other major cardiovascular risk factors.
Diabetes has also been found to increase cardiovascular events
and death after stroke [32–34]. A study based on the Northern
Sweden MONICA Stroke Registry showed reduced survival
after stroke in diabetic patients compared to non-diabetic pa-
tients and an even more pronounced reduction in survival in
diabetic women [35].
The mechanisms responsible for these sex differences in
diabetes-related cardiovascular risk remain to be elucidated.
Possible Causes of the Sex Differences
in Diabetes-Associated Cardiovascular Risk
Multiple mechanisms may be responsible for the sex differ-
ence in diabetes-associated risk of cardiovascular disease.
Postulated underlying causes include increases in the preva-
lence of classical cardiovascular risk factors and in the effects
of the risk factors on the development of cardiovascular dis-
ease in diabetic persons, decreases in risk factor control, and
interference with protective mechanisms in the vascular wall
in women with diabetes.
Cardiovascular Risk Factors
It has been postulated that women have to ‘travel further’ than
men to develop diabetes [24••]. Observed differences in prev-
alence of risk factors in individuals with diabetes compared
with those without diabetes are often greater in women. These
risk factors include waist-to-hip ratio, obesity, insulin resis-
tance, dyslipidaemia, hypertension, coagulation factors, endo-
thelial dysfunction, and systemic inflammation [36–39].
Some cardiovascular risk factors may have a greater effect
on absolute risk in diabetic women than in diabetic men [38].
Endothelial function has been shown to be impaired to a
greater extent in premenopausal women with type 2 diabetes
than in men with type 2 diabetes [40]. Furthermore, low-grade
inflammation may have a greater role in perturbing insulin
action in women, and inflammatory factors may interact with
female sex hormones, resulting in a decrease in the protective
effects of oestrogens on body fat distribution and insulin ac-
tion [41].
Management, Treatment and Control of Cardiovascular
Risk Factors
In persons with diabetes, a gender disparity in the treatment
and control of cardiovascular risk factors has been reported
[24••, 42, 43]. However, these treatment differences are less
evident in more recent studies, and some evidence of higher
treatment rates in women has emerged [18••, 44–46•]. Even
when treated similarly, control of hyperglycaemia and major
cardiovascular risk factors appears to be less satisfactory in
women than in men. Data from medical records of 286,791
Spanish patients with type 2 diabetes (153,987 men and 132,
804 women, of whom 22.3 and 13.8 % had prior cardiovas-
cular disease, respectively), control of HbA1c, blood pressure
and LDL cholesterol was worse in women, with or without
prior cardiovascular disease, although differences were small
[44]. In a cross-sectional survey at 10 outpatient diabetes
clinics in Italy (MIND.IT Study, n=1297 men and n=1168
women with no previous cardiovascular events), optimal tar-
gets for HbA1c, LDL cholesterol, HDL cholesterol and sys-
tolic blood pressure were significantly less frequently
achieved by women than by men after adjustment for
overweight/obesity and age [45]. Similarly, an Italian study
of patients with type 2 diabetes attending 19 hospital-based
diabetes clinics (RIACE Study, n=15,773) revealed less suc-
cessful achievement of treatment targets for HbA1c, LDL,
HDL and non-HDL cholesterol, and obesity in women than
in men, even after adjustment for treatment, BMI, duration of
diabetes and age [46•]. The difference in systolic blood pres-
sure control was not significant after adjustment for age.
The observation that women with diabetes are less fre-
quently on target for cardiovascular risk factors suggests that
the increased treatment rate in women is insufficient to bridge
the gap in cardiovascular risk burden between the sexes. The-
se findings and the lack of evidence for reduced drug efficacy
in women compared with men suggest the involvement of
other mechanisms. Whether there is a role for hormonal, life-
style, cultural and/or socioeconomic factors in sex-specific
risk factor control is unclear.
Sex Hormones and Diabetes
Several studies have suggested that endogenous sex hormones
play a role in type 2 diabetes development [47–50]. In partic-
ular, significant sex differences were observed for the associ-
ation between endogenous testosterone and risk of type 2 di-
abetes [47]. Ding et al. showed that in postmenopausal wom-
en, testosterone levels are related to increased risk of develop-
ing type 2 diabetes [48]. The authors hypothesized that this
potentially causal relationship may be due to testosterone-
dependent impairment of insulin-mediated glucose uptake
and increase in lipogenesis [48]. Furthermore, Kalyani et al.
reported that in postmenopausal women, after adjustment for
body mass and insulin resistance, the association between
higher bioavailable testosterone and type 2 diabetes incidence
was no longer present, suggesting that adiposity and insulin
resistance mediate this association [50]. Androgen excess in
women likely impairs insulin action, e.g. women with poly-
cystic ovarian syndrome (PCOS) are predisposed to type 2
diabetes [51].
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Recently, positive correlations have been reported between
both testosterone and oestrogen levels and incidence of type 2
diabetes in postmenopausal women [52]. However, other pub-
lished data question the existence of a causative link between
oestrogen and diabetes [48, 50].Moreover, it has been hypoth-
esized that the increased cardiovascular risk in postmenopaus-
al women could be partially caused by the loss of protection
conferred by endogenous oestrogen [53]. However, a causal
relationship between sex hormones and diabetes-associated
cardiovascular risk has not been demonstrated.
Future Perspectives
The often dramatically higher cardiovascular risk that is ob-
served in women with diabetes highlights the need for more
intensive treatment and optimized management of cardiovas-
cular risk factors in diabetic and pre-diabetic women [23, 35].
The onset of type 2 diabetes is believed to occur years before
its clinical diagnosis [54]. This suggests that individuals with
pre-diabetes are being exposed to cardiovascular risk factors
associated with diabetes even before the disease becomes
manifest. Screening for pre-diabetes, combined with more
stringent follow-up of women at high risk for diabetes, such
as those with a history of gestational diabetes, polycystic ova-
ry syndrome, or postmenopausal women, could have a sub-
stantial impact on the prevention of cardiovascular disease.
The reasons for the increased cardiovascular risk in women
with diabetes are unclear, and this disparity is unlikely to be
explained by gender differences in pharmacotherapy [24, 31].
As discussed before, sex differences in cardiovascular risk
factors have been reported, but are unlikely to be the only
cause of the excess cardiovascular risk in diabetic women [31].
Further sex-specific analyses of large-scale epidemiological
studies that include individuals with and without diabetes are
needed to elucidate the causes of the increased cardiovascular
complications observed in women with diabetes. The ongoing
Maastricht Study, which aims to include n=10,000 men and
women with a large proportion of individuals with diabetes in
whom extensive phenotyping will be performed using state-of-
the-art techniques is designed to address this need. Collection of
detailed information on conventional and emerging cardiovascu-
lar risk factors, socioeconomic and lifestyle factors, preclinical
cardiac and vascular abnormalities and cardiovascular outcomes
(among other comorbidities) in bothmen andwomen is expected
to contribute importantly to the understanding of sex-specific
mechanisms underlying diabetic complications. Begun in 2010,
the Maastricht Study is one of the largest prospective cohort
studies of its kind [55]. Enhanced elucidation of sex-specific risk
factors will provide opportunities for the development of novel
prevention and treatment strategies. Because gender disparities in
risk factor control exist even when women and men are treated
similarly, better understanding of the sex-specific effects of risk
factor-modifying interventions such as pharmacotherapy or life-
style changes is much needed. Future trials of risk factor man-
agement in individuals with diabetes should take into account sex
differences in order to develop more effective prevention and
treatment strategies aimed at reducing cardiovascular events in
both women and men.
Conclusion
Several studies have demonstrated that diabetes is more strongly
associated with cardiovascular risk in women than it is in men.
The underlying causes for the diabetes-related sex difference in
cardiovascular risk are still unclear. Although roles of sex hor-
mones and menopause have been hypothesized, sex differences
in diabetes-associated cardiovascular risk factors are mainly be-
lieved to be responsible for this increased risk. Current evidence
indicates that there is room for improvement of cardiovascular
risk factor control in diabetic women. Moreover, increased
screening for pre-diabetes and more stringent follow-up and risk
factor management in female patients could strongly improve the
prevention of cardiovascular disease. However, large-scale epi-
demiological studies are needed to further elucidate the factors
that underlie the excess cardiovascular risk in diabetic women.
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